Shanghai HaiHe Pharmaceutical Co., Ltd.
https://www.haihepharma.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shanghai HaiHe Pharmaceutical Co., Ltd.
Biotechs Stage No-Show As China’s STAR Market Marks Third Anniversary
To date this year, not a single innovative drug-focused biotech has filed for an initial public offering on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Apart from a suspected tightening of listing rules, IPO disclosures and the plummeting share prices of public companies seem to be looming large over bioventures aiming considering floating on the bourse.
AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.
AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Deal Snapshot: Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.
Everest Medicines Sees Differentiated Strategy Leading To Trodelvy Success
Focused on the Chinese Market, the Shanghai-based bioventure is pushing ahead with a differentiated clinical development strategy for its top in-licensed asset Trodelvy, as an uphill fight looms over the antibody-drug conjugate therapy outside of China, the company’s president says in an interview.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals